Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation

Clinical Chemistry

Volumn 57, Issue 10, 2011, Pages 1387-1389

  Hutchison, Colin A ^a   Landgren, Ola ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN;

ADAPTIVE IMMUNITY; BACTERIAL INFECTION; DISEASE MARKER; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOASSAY; IMMUNONEPHELOMETRIC ASSAY; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; NOTE; REFERENCE VALUE;

ADAPTIVE IMMUNITY; BIOLOGICAL MARKERS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN LIGHT CHAINS; INFLAMMATION; REFERENCE VALUES;

EID: 80053423537     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.169433     Document Type: Note

References (18)

1. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
2. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90. (Pubitemid 38500312)
3. Soloman A. Light chains of human immunoglobulins. Methods Enzymol 1985;116:101-21.
4. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972;51:2162-74.
5. 131]Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967;18:395-407.
6. Bradwell AR, Carr-Smith HD, Mean GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80. (Pubitemid 32275810)
7. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413-22. (Pubitemid 351550561)
8. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
9. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44. (Pubitemid 34925779)
10. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
11. Gottenberg J. Free light chains of immunoglobulins as disease activity markers in autoimmune diseases. Hematol Rep 2010;2:14.
12. Jolly M, Mikolaitis AR, Block JA, Sequeira W. Free light chains: predictor of emergent medical care utilization in lupus. Hematol Rep 2010;2:E44.
13. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010;28:773-9.
14. Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009;114:4928-32.
15. Stringer S. Polyclonal FLC and chronic kidney disease. Hematol Rep 2010;2:6.
16. Dispenzieri A, Katzmann JA, Kyle RA, Larson D, Rajkumar SV. Non-clonal serum immunoglobulin free light chains (FLC) as markers of overall survival. Hematol Rep 2010;2:12.
17. Dürig J, Eisele L, Hüttmann A, Dührsen U, Führer A, Kieruzel S, et al. Polyclonal free light chain elevation and mortality in the German Heinz Nixdorf Recall Study. Hematol Rep 2010;2:13.
18. Lukacik P, Hughes RG, Pratt G, Hutchison CA, Mead GP. Differences between C-reactive protein and free light chain production after trauma. Hematol Reps. 2010;2:E50.